Mistletoe Therapy for Cancer: What the Research Actually Shows

By Dr. Lena Suhaila, ND, FABNO

Mistletoe therapy comes up in almost every integrative oncology consultation I have, whether I raise it or the patient does. Someone mentions it on a forum, or a European relative brings it up, or a Johns Hopkins headline catches their eye. The questions that follow tend to be the same: what is it actually, does it work, is it safe alongside chemotherapy, and why isn't it more widely used in the US. What follows is the evidence, the legitimate questions, and what the therapy actually involves.

What mistletoe therapy is

European mistletoe (Viscum album) is a semi-parasitic plant, and extracts of it have been used in European integrative oncology since the 1920s, beginning with Rudolf Steiner's work within anthroposophic medicine. Today, standardized extracts are among the most widely prescribed adjunct cancer therapies in German-speaking Europe, where an estimated 70 to 80 percent of cancer patients receive some form of it during their care.

The active compounds are mistletoe lectins (primarily ML-I, ML-II, and ML-III), viscotoxins, polysaccharides, and flavonoids. These have been studied extensively in vitro and in animal models, where they demonstrate immune-modulating effects, direct cytotoxicity against tumor cells, and induction of apoptosis. In clinical use, mistletoe is typically administered as a subcutaneous injection, though intravenous and intratumoral routes are also used in specific contexts.

Commercial preparations include Iscador, Helixor, AbnobaVISCUM, and Eurixor. They differ in host tree species, apple, pine, oak, elm, fir, fermentation status, and manufacturing process, and these differences matter clinically. Different preparations tend to suit different cancer types, constitutions, and clinical goals. For a thorough breakdown of host tree selection and formulation decisions, Mistletoe and the Emerging Future of Integrative Oncology by Dr. Nasha Winters, ND, FABNO, and Dr. Steven Johnson, DO, is the most comprehensive English-language resource available. It grew out of the Physicians Association for Anthroposophic Medicine practitioner training, which is where I completed my own training in mistletoe therapy, and it covers the science, immunology, and clinical application in depth that a single article cannot hold.

What the evidence actually shows

The European clinical literature on mistletoe is substantial. More than fifty clinical trials have examined its effects on quality of life, immune function, treatment tolerance, and survival. Studies from Germany, Switzerland, and Austria consistently show improvements in quality of life during chemotherapy, reductions in fatigue and nausea, and better immune parameters in patients receiving mistletoe alongside standard treatment.

The strongest and most replicated finding is quality of life benefit. A large observational study in Germany involving over ten thousand patients reported significant improvements in fatigue, sleep, pain, and overall well-being during chemotherapy in patients receiving mistletoe. Randomized trials in breast cancer, colorectal cancer, and pancreatic cancer have shown similar patterns: patients on mistletoe tolerate their treatment better, report fewer side effects, and maintain better daily function.

The survival data is more mixed. Some studies show survival benefit, others don't, and methodological quality varies across the literature. The US National Cancer Institute notes in its official summary that while some studies show favorable results, many have design limitations, and conclusions about survival benefit remain incomplete.

The Phase I trial at Johns Hopkins, led by Dr. Channing Paller, used intravenous Helixor M in patients with advanced solid tumors who had exhausted standard options. The therapy was well tolerated, side effects were manageable, and a subset of patients showed disease stability or improved quality of life. Follow-up Phase II trials are underway.

The new science: immunogenic cell death

The most significant development in mistletoe research in recent years is the confirmed discovery of immunogenic cell death, or ICD. This is a specific form of cancer cell death that does not just kill the cell but triggers a downstream immune response that helps the body recognize and attack remaining cancer cells.

Mistletoe extracts trigger endoplasmic reticulum stress in cancer cells, leading to calreticulin exposure on the cell surface in 18 to 51 percent of affected cancer cells, and a sevenfold increase in ATP release. Both are hallmarks of immunogenic cell death. Mistletoe is not only killing cancer cells directly; it is turning those dying cells into a signal that activates the immune system more broadly. This changes how we understand the mechanism, and it has direct implications for how mistletoe interacts with immunotherapy drugs.

Mistletoe and immunotherapy

A real-world data study examined 415 patients with advanced or metastatic non-small-cell lung cancer, comparing outcomes between patients receiving PD-1/PD-L1 checkpoint inhibitors alone and patients receiving checkpoint inhibitors plus Viscum album. Patients in the combination group lived a median of 13.8 months compared to 6.8 months in the control group. In PD-L1-positive patients receiving first-line immunotherapy, adding mistletoe was associated with a 56 percent reduction in the adjusted hazard of death.

415 patients and a seven-month survival difference is not a number to set aside. The mechanism is increasingly clear: mistletoe's induction of immunogenic cell death creates the conditions that checkpoint inhibitors are designed to exploit. When cancer cells die in a way that activates the immune system, drugs that remove the brakes on that immune system have more to work with. For patients on immunotherapy, this data belongs in the conversation.

Cancer type by cancer type

Mistletoe has been studied across bladder, breast, cervical, ovarian, colorectal, gastric, pancreatic, glioma, head and neck, lung, melanoma, and osteosarcoma. The evidence is not uniform, and clinical application reflects that.

Pancreatic cancer has some of the strongest specific data. The Troger 2013 randomized controlled trial showed improved overall survival in locally advanced or metastatic pancreatic cancer with Viscum album extract. More recent analysis showed median survival extending from 8.6 months with chemotherapy alone to 11.2 months with added mistletoe, and to 18.9 months when hyperthermia was included. For a cancer with extremely limited options and a poor prognosis, those numbers carry clinical weight.

Breast cancer has a substantial evidence base for quality of life. Multiple randomized studies show that breast cancer patients receiving adjuvant chemotherapy who were additionally treated with mistletoe reported significant improvements in quality of life, reduced side effects, and better treatment tolerance. Chemotherapy tolerance determines whether patients can complete the treatment that may keep them alive.

Hepatocellular carcinoma is described in recent reviews as another highly responsive malignancy. Phase II trials examining Viscum fraxini in advanced hepatocellular carcinoma have found disease stabilization and quality of life benefits in a patient population with very few options.

Colorectal cancer has been studied primarily in the context of chemotherapy support. A large multicenter observational study in non-metastatic colorectal cancer found that concurrent mistletoe therapy was associated with improved quality of life and better treatment completion rates.

Glioma and primary brain tumors require careful judgment. Mistletoe is generally contraindicated or requires close monitoring in the presence of active brain metastases or primary brain tumors with significant edema risk, because the immune activation it produces can increase intracranial pressure. Mistletoe should only be used here under the supervision of someone trained in it.

How the therapy is administered

Subcutaneous injection is the most common route. Patients are trained to self-administer at home after initial supervised dosing, usually two to three times per week on an ongoing basis. Dosing starts low and titrates upward based on individual response.

A local reaction at the injection site, a small red area, mild itch, or a low-grade fever, is part of how the therapy works rather than a side effect to suppress. Those local reactions guide dose titration. The clinical goal is to reach a specific immune response without pushing past it.

Intravenous mistletoe is used in clinic under medical supervision, typically for more advanced disease or when specific therapeutic goals call for higher systemic exposure. Intratumoral injection is reserved for specific clinical situations and used less often.

Safety considerations

Mistletoe is generally well tolerated. The most common side effects are local injection site reactions and occasional low-grade fevers. Significant allergic reactions are rare but possible, which is why initial dosing is always supervised.

Mistletoe can interact with immunosuppressive medications, including those used after organ transplant. It should be paused around surgery. It is not appropriate during pregnancy. In patients on checkpoint inhibitor immunotherapy, combined use requires case-by-case clinical evaluation as the evidence on this combination continues to develop.

In the US, mistletoe extracts are not FDA-approved and are obtained through compounding pharmacies or prescription from physicians trained in the therapy. That limits availability here despite its long clinical history in Europe.

When mistletoe is worth considering

Mistletoe is worth a serious conversation if you are in active chemotherapy or radiation and want support with treatment tolerance, in survivorship and want to support long-term immune function, or managing advanced disease and looking for integrative options alongside conventional care. The therapy is not a replacement for standard treatment. It is an adjunct with a real evidence base and a century of clinical use behind it.

Work with me

I work with cancer patients at every stage of diagnosis and treatment, virtually, from anywhere. If you want to talk through whether mistletoe makes sense for your situation, start here.

References

1. Büssing A, Schietzel M, Schweizer K. Mistletoe extracts in oncology: basic findings and clinical research. Integr Cancer Ther. 2008.

2. Kienle GS, Kiene H. Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther. 2010;9(2):142-157.

3. Troger W, Galun D, Reif M, Schumann A, Stankovic N, Milicevic M. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. Eur J Cancer. 2013;49(18):3788-3797.

4. Troger W, et al. Additional therapy with a mistletoe product during adjuvant chemotherapy of breast cancer patients improves quality of life: an open randomized clinical pilot trial. Evid Based Complement Alternat Med. 2014.

5. Paller CJ, Wang L, Fu W, et al. Phase I trial of intravenous mistletoe extract in advanced cancer. Cancer Res Commun. 2023;3(2):338-346.

6. Axtner J, et al. Patients with advanced or metastasised non-small-cell lung cancer with Viscum album L. therapy in addition to PD-1/PD-L1 blockade: a real-world data study. Cancers. 2024;16(8):1609.

7. Loef M, Walach H. Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis. BMC Complement Med Ther. 2020;20:227.

8. Pelzer F, Loef M, Martin DD, Baumgartner S. Cancer-related fatigue in patients treated with mistletoe extracts: a systematic review and meta-analysis. Support Care Cancer. 2022;30:6405-6418.

9. National Cancer Institute. Mistletoe Extracts (PDQ): Health Professional Version. National Institutes of Health. Updated 2023.

10. Winters N, Johnson S. Mistletoe and the Emerging Future of Integrative Oncology. Portal Books. 2023.